News25/Ratings0
Latest news
25 items- PRBIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial OfficerREDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se
- PRBridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM) –New Drug Application (NDA) for infigratinib for the treatment of cholangiocarcinoma accepted by the U.S. Food and Drug Administration (FDA) under Priority Review designation and Real-Time Oncology Review (RTOR) pilot program, designed to expedite the delivery of safe and effective cancer treatments to patients –Initiated two new clinical trials since las
- SECSEC Form 15-12B filed15-12B - Eidos Therapeutics, Inc. (0001731831) (Filer)
- INSIDERSEC Form 4: C Jonathan Fox gifted 500 units of Common Stock, decreasing ownership by 100% to 0 units4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- INSIDERSEC Form 4 filed by Douglas Rohlen4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- INSIDERSEC Form 4 filed by Franco Valle4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- INSIDERSEC Form 4: Cameron Turtle decreased ownership by 100% to 0 units4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- INSIDERSEC Form 4 filed by J. Ali Satvat4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- INSIDERSEC Form 4 filed by William Lis4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- INSIDERSEC Form 4 filed by Sawochka Suzanne Hooper4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- INSIDERSEC Form 4: Uma Sinha gifted 3,000 units of Common Stock, decreasing ownership by 100% to 0 units4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- SECSEC Form EFFECT filedEFFECT - Eidos Therapeutics, Inc. (0001731831) (Filer)
- SECSEC Form POS AM filedPOS AM - Eidos Therapeutics, Inc. (0001731831) (Filer)
- SECSEC Form S-8 POS filedS-8 POS - Eidos Therapeutics, Inc. (0001731831) (Filer)
- SECSEC Form S-8 POS filedS-8 POS - Eidos Therapeutics, Inc. (0001731831) (Filer)
- SECSEC Form S-8 POS filedS-8 POS - Eidos Therapeutics, Inc. (0001731831) (Filer)
- SECSEC Form 25-NSE filed25-NSE - Eidos Therapeutics, Inc. (0001731831) (Subject)
- SECSEC Form 8-K filed8-K - Eidos Therapeutics, Inc. (0001731831) (Filer)
- PRBridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders. The merger reunites the teams at BridgeBio and Eidos and allows BridgeBio to deploy its full clinical and commercial infrastructure to support the development and global commercialization plans underway for Eidos’ acoramidis, a potential best-in-class therapy for patients with transthyretin (TTR) amyloidosis
- SECSEC Form 8-K filed8-K - Eidos Therapeutics, Inc. (0001731831) (Filer)
- PRStockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBio’s acquisition of all of the outstanding shares of Eidos common stock that BridgeBio does not already own. The merger is expected to close on or about January 26, 2021, subject to the satisfaction or waiver of other conditions to closing. At a special meeting of Eidos stockholders held virtually today, Eidos stockholders approved the adoption of the previously disclosed merger agreement with B
- SECSEC Form 4: Uma Sinha sold $1,238,856 worth of Common Stock (10,000 units at $123.89), decreasing ownership by 3% to 306,525 units4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
- SECSEC Form 425 filed425 - Eidos Therapeutics, Inc. (0001731831) (Subject)
- PRBridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for MergerPALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to the conditions of their previously announced merger agreement, is expected to close on or about January 26, 2021. The closing of the transaction is subject to the receipt of approvals from BridgeBio and Eidos stockholders at special meetings of each company’s stockholders, both of which are scheduled for January 19, 2021, and the satisfaction or waiver of other conditions to
- SECSEC Form 4: Franco Valle exercised 3,247 units of Common Stock at a strike of $7.24 and sold $407,580 worth of Common Stock (3,247 units at $125.53)4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)
EIDX FAQ
5 questionsWhere does EIDX stock trade?
Eidos Therapeutics, Inc. (EIDX) is listed on NASDAQ.What sector and industry is EIDX in?
Eidos Therapeutics, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Eidos Therapeutics, Inc. go public?
Eidos Therapeutics, Inc. (EIDX) completed its IPO in 2018.What companies are similar to EIDX?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare EIDX side-by-side with any of them on Quantisnow.How can I track EIDX on Quantisnow?
Quantisnow aggregates Eidos Therapeutics, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EIDX to receive live email and push alerts on every new disclosure.